Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
A novel immune-targeting drug is turning heads in eczema treatment. Rezpegaldesleukin, which works by boosting regulatory T cells, significantly cut disease severity in adults with moderate-to-severe atopic dermatitis compared to placebo in a 16-week phase 2 trial. The drug also showed a favorable safety profile, with no treatment-related deaths reported.
Rezpegaldesleukin, an interleukin-2 receptor agonist, is making waves in dermatology. The drug selectively expands regulatory T cells (Tregs) — immune cells that help keep inflammation in check — and showed significant improvements in skin clearance and itch reduction in adults with moderate-to-severe atopic dermatitis (AD) in the phase 2b REZOLVE-AD trial, published in The Lancet.
The randomized, double-blind, placebo-controlled trial enrolled 393 biologic-naive adults across 107 sites in 10 countries. Participants received one of three dosing regimens of rezpegaldesleukin or placebo over 16 weeks.
This is reportedly the first large placebo-controlled trial to validate the immunomodulatory role of Tregs in a clinical setting — 25 years after their discovery. With a rapid onset of efficacy and a clean safety profile, rezpegaldesleukin could offer a meaningful new option for the millions of patients living with hard-to-treat eczema.
